Clinical Trials Using Talazoparib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Talazoparib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-24 of 24
  • Testing Maintenance Therapy for Small Cell Lung Cancer in Patients with SLFN11 Positive Biomarker

    This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PARPs are proteins that help repair damage to DNA, the genetic material that serves as the body’s instruction book. Changes (mutations) in DNA can cause tumor cells to grow quickly and out of control, but PARP inhibitors like talazoparib may keep PARP from working, so tumor cells can’t repair themselves, and they stop growing. Giving atezolizumab in combination with talazoparib may help lower the chance of extensive-stage small cell lung cancer growing and spreading compared to atezolizumab alone.
    Location: 453 locations

  • I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
    Location: 22 locations

  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). ********************************************************************************************* ********************************************************************************* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org / news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************************************* *********************************************************************************
    Location: 11 locations

  • Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

    This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
    Location: 10 locations

  • Talazoparib and Axitinib for the Treatment of Metastatic or Unresectable Kidney Cancer

    This phase Ib / II trial studies the side effects and best dose of talazoparib and how well it works when given together with axitinib for the treatment of kidney cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Talazoparib prevents cancer cells from repairing their DNA, which is the body's genetic instruction book. Without repair, cancer cells collect errors in their DNA and eventually die. Axitinib works by blocking the blood flow to cancer cells, and this blocking action stops the cancer cells from growing and spreading. Giving talazoparib and axitinib may be more effective in shrinking or stabilizing kidney cancer compared to giving either drug on its own.
    Location: 7 locations

  • Talazoparib and Avelumab for the Treatment of Metastatic Renal Cell Carcinoma

    This phase II trial studies how well talazoparib and avelumab work in treating patients with renal cell carcinoma (the most common kidney cancer) that has spread to other places in the body (metastatic). Avelumab is an antibody that recognizes and attaches to a molecule called PD-L1. PD-L1 is found on the surface of some tumor cells, where it functions like a shield to prevent the tumor cells from being attacked by the immune system. When avelumab attaches to PD-L1, it may break up the protective shield and may help the immune system recognize and kill tumor cells. Talazoparib inhibits (stops) the normal activity of certain molecules called PARPs. PARPs are proteins that help repair damage to DNA, the genetic material that serves as the body’s instruction book. Changes (mutations) in DNA can cause tumor cells to grow quickly and out of control. But PARP inhibitors like talazoparib have been shown to keep PARP from working, so tumor cells can’t repair themselves, and they stop growing. Giving avelumab and talazoparib together may be more effective than giving either drug alone in treating patients with renal cell cancer.
    Location: 7 locations

  • Study of RP-3500 in Advanced Solid Tumors

    The primary purpose of this study is to study the maximum tolerated dose (MTD) of orally-administered RP-3500 alone or in combination with talazoparib, a PARP inhibitor, in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP-3500 alone or in combination with talazoparib, examine both the pharmacokinetics (PK)and pharmacodynamics (PD)and investigate its anti-tumor activity in solid tumors.
    Location: 5 locations

  • Talazoparib and Gedatolisib in Treating Patients with Advanced Triple Negative or BRCA1 / 2 Positive, HER2 Negative Breast Cancer

    This phase I / II trial studies the best dose of talazoparib when given together with gedatolisib and to see how well they work in treating patients with triple negative or BRCA1 / 2 positive, HER2 negative breast cancer that has spread to other places in the body (advanced) and cannot be removed by surgery. Talazoparib and gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Talazoparib blocks an enzyme called PARP. Talazoparib causes cancer cells to die by breaking the tumor DNA and then stopping the tumor from repairing the damaged DNA. Gedatolisib blocks two receptors called PI3K and mTOR. By blocking these pathways, gedatolisib may cause cancer cells to die and stop growing.
    Location: 5 locations

  • Avelumab, Talazoparib, and Axitinib in Treating Patients with MSS, MSI-H, and POLE-Mutated Recurrent or Persistent Endometrial Cancer

    This phase II trial studies how well avelumab together with talazoparib or axitinib work in treating patients with microsatellite stable (MSS), high frequency microsatellite instability (MSI-H), and polymerase e (POLE)-mutated endometrial cancer that has come back (recurrent) or does not go to remission despite treatment (persistent). Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Talazoparib and axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving avelumab together with talazoparib or axitinib may work better in treating MSS endometrial cancer compared to avelumab alone.
    Location: 5 locations

  • Talazoparib for the Treatment of Cohesin-Mutated Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    This phase I trial studies how well talazoparib works in treating patients with cohesion-mutated acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) or myelodysplastic syndrome. Talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations

  • A Study of ZN-c3 in Participants With Solid Tumors

    This is a Phase 1 / 2 open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3 alone and in combination with other drugs.
    Location: 3 locations

  • Sacituzumab Govitecan and Talazoparib for the Treatment of Stage IV Triple-Negative Breast Cancer

    This phase Ib / II trial studies the side effects and best dose of sacituzumab govitecan and talazoparib in treating patients with stage IV triple-negative breast cancer. Sacituzumab govitecan is an antibody-drug conjugate which means it’s made up of an antibody attached to an anticancer drug. An antibody is a protein normally made by the immune system (the system in the body that fights off diseases). Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the tumor cells from growing / spreading. Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged deoxyribonucleic acid (DNA) (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in tumor cells so that the cancer cannot fix its damaged DNA. Sacituzumab govitecan and talazoparib may help stop tumors from growing and spreading by administering an anticancer drug directly to the cancerous tumor(s) through sacituzumab govitecan and by stopping the cancer’s cells from fixing its damaged DNA through talazoparib.
    Location: 3 locations

  • Talazoparib and Avelumab for the Treatment of Advanced Breast Cancer, the TALAVE study

    This phase I / II trial studies the side effects of talazoparib and avelumab for the treatment of breast cancer that has spread to other places in the body (advanced). Avelumab is a type of protein that recognizes and attaches to other proteins in the body. It specifically recognizes and attaches to a protein called PD-L1 which is found on the surface of some cancer cells, where it acts to protect those cells from being attacked by the immune system (the part of the body that fights infection but which is also involved in fighting cancer). When avelumab attaches to PD-L1, it stops PD-L1 from working and so allows the immune system to recognize and kill the cancer cells. Talazoparib is a drug that stops the activity of a protein called PARP. PARP is involved in repairing damage to the deoxyribonucleic acid (DNA) within cells. When PARP is turned off by talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells. Giving talazoparib and avelumab may have the capacity to increase the response to immunotherapy.
    Location: 3 locations

  • A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

    This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is dose escalation and Part 2 is a Simon 2-Stage design
    Location: 3 locations

  • Measuring the Effects of Talazoparib in Patients with Advanced Cancer and DNA Repair Variations

    This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage response genes who have or have not already been treated with another PARP inhibitor. Talazoparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. All patients who take part on this study must have a gene aberration that changes how their tumors are able to repair DNA. This trial may help scientists learn whether some patients might benefit from taking different PARP inhibitors “one after the other" and learn how talazoparib works in treating patients with advanced cancer who have aberration in DNA repair genes.
    Location: 2 locations

  • Talazoparib and Low-Dose Temozolomide in Treating Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

    This phase II trial studies how effective talazoparib and temozolomide are for treating patients with extensive-stage small cell lung cancer that has come back (relapsed) after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide may work better in treating patients with extensive-stage small cell lung cancer than either one alone.
    Location: 2 locations

  • Talazoparib and Belinostat for the Treatment of Metastatic or Unresectable Breast Cancer, Metastatic Castration Resistant Prostate Cancer, or Metastatic Ovarian Cancer

    This phase I trial is to find the best dose of belinostat when given together with talazoparib in treating patients with breast cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable), metastatic prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), or metastatic ovarian cancer. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving talazoparib and belinostat may kill more tumor cells.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Talazoparib, Radiation Therapy, and Atezolizumab for the Treatment of gBRCA 1 / 2 Negative, PD-L1 Positive, Metastatic Triple-Negative Breast Cancer, TARA Study

    This phase II trial investigates how well the combination of talazoparib, radiation therapy, and atezolizumab work in treating patients with germline (g) BRCA 1 / 2 negative, PD-L1 positive, triple-negative breast cancer that has spread to other places in the body (metastatic). Genes are like an instruction manual for the body. Germline mutation is a gene change in a body's reproductive cell (egg or sperm) that becomes incorporated into the DNA of every cell in the body of the offspring. BRCA 1 and 2 are genes that normally help to suppress cell growth. Breast cancers in women with a harmful BRCA1 mutation tend to be "triple-negative cancers" (that is, the breast cancer cells do not have estrogen receptors, progesterone receptors, or large amounts of HER2 / neu protein), which generally have poorer prognosis than other breast cancers. Talazoparib is a targeted therapy. Talazoparib blocks an enzyme called PARP. PARP enzymes are involved in cellular growth regulation. Talazoparib causes cancer cells to die by damaging the genetic structure of tumor and then stopping the tumor cells from repairing the damage. PD-L1 is a protein that acts as a kind of “brake” to keep the body’s immune responses under control. Radiation therapy increases PD-L1 expression on cells making them more sensitive to atezolizumab. Atezolizumab is an immunotherapy drug that blocks the activity of PD-L1. By blocking PD-L1, a specific type of immune cells called T-cells function better and the immune system can better find and kill cancer cells. Talazoparib may enhance the effect of radiation therapy and atezolizumab in treating gBRCA 1 / 2 negative, PD-L1 positive, metastatic triple-negative breast cancer patients.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Nivolumab plus Talazoparib for the Treatment of Unresectable or Metastatic Melanoma in Patients with Mutations in BRCA or BRCA-ness

    This phase II trial studies how well the use of nivolumab in combination with talazoparib works for the treatment of melanoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Patients must also have specific genetic changes (mutations), that can be targeted by drugs (BRCA or BRCA-ness). Immunotherapy with monoclonal antibodies, such as nivolumab may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. PARPs are proteins that help repair damage to DNA, the genetic material that serves as the body’s instruction book. Mutations in DNA can cause tumor cells to grow quickly and out of control, but PARP inhibitors such as Talazoparib may keep PARP from working, so tumor cells can’t repair themselves, and they stop growing. Giving nivolumab and talazoparib as a combination treatment may have a greater effect on melanoma that if each drug was given by itself.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Talazoparib for the Treatment of BRCA 1 / 2 Mutant Metastatic Breast Cancer

    This phase II trial studies how well talazoparib works for the treatment of breast cancer with a BRCA 1 or BRCA 2 gene mutation that has spread to other places in the body (metastatic). Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called “poly (ADP-ribose) polymerases” also called “PARPs”. PARPs are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as talazoparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become tumor cells. Tumor cells may be killed by a study drug, like talazoparib, that stops the normal activity of PARPs. Talazoparib may be effective in the treatment of metastatic breast cancer with BRCA1 or BRCA2 mutations.
    Location: 2 locations

  • Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers

    This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Open-Label Extension and Safety Study of Talazoparib

    This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.
    Location: 2 locations

  • Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer or Other Solid Tumors

    This phase II trial studies how well talazoparib works in treating patients with breast cancer (BRCA)1 and BRCA2 wild-type (lacking an inherited form of the BRCA1 or BRCA2 gene mutation), triple-negative (estrogen receptor-, progesterone receptor-, and HER2-negative) breast cancer or other solid tumors with faulty deoxyribonucleic acid repair mechanisms or HER2-negative breast cancer with evidence of a hereditary breast cancer syndrome or evidence of genetic changes in the tumor tissue that has come back (recurrent) or spread to other places in the body (metastatic). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

    This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement (recurrent), do not respond to treatment (refractory), or have spread to other parts of the body (advanced or metastatic), and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
    Location: M D Anderson Cancer Center, Houston, Texas